QIAGEN(QGEN) - 2023 Q2 - Earnings Call Presentation

Q2 2023 Performance - QIAGEN's Q2 2023 net sales reached $495 million, a decrease of 4% compared to Q2 2022 [8] - Non-COVID product groups grew by 9% CER [4, 8] - Adjusted diluted EPS was $051, matching Q2 2022 [13] - The company invested approximately 10% of sales into R&D in H1 2023 [19, 41] Product Group Performance - Sample technologies experienced a sales decrease of 7% CER [9] - Diagnostic solutions sales increased by 13% CER, with QuantiFERON sales growing by 27% CER [16] - Genomics/NGS sales increased by 12% CER [9] - COVID-19 product groups experienced a sales decline of 59% CER [8] Regional Performance - Americas region saw a 4% CER sales increase, driven by strong QuantiFERON and QIAcuity sales in the U S [17] - EMEA region experienced a 7% CER sales decrease [17] - Asia-Pacific/Japan region saw a 17% CER sales decrease, although non-COVID sales in China were largely unchanged [17] FY 2023 Outlook - The company updated its FY 2023 net sales outlook to ≥ $197 billion CER [13, 50] - Adjusted EPS outlook is ≥ $207 CER [13, 50] - The updated outlook reflects a significant drop in COVID-19 testing and volatility in OEM business [14]